Rational design of therapeutic mAbs against aggregation through protein engineering and incorporation of glycosylation motifs applied to bevacizumab

Rational Design of Biobetters with Enhanced Stability

(2015) Fabienne Courtois et al.   JOURNAL OF PHARMACEUTICAL SCIENCES

Aggregation risk prediction for antibodies and its application to biotherapeutic development

(2015) Olga Obrezanova et al.   mAbs

Effect of Polyethylene Glycol Conjugation on Conformational and Colloidal Stability of a Monoclonal Antibody Antigen-Binding Fragment (Fab′)

(2015) Cristopher Roque et al.   MOLECULAR PHARMACEUTICS

Avoiding antibody aggregation during processing: Establishing hold times

(2014) Varsha Joshi et al.   Biotechnology Journal

Capability measurement of size-exclusion chromatography with a light-scattering detection method in a stability study of bevacizumab using the process capability indices

(2014) Alexis Oliva et al.   JOURNAL OF CHROMATOGRAPHY A

Early developability screen of therapeutic antibody candidates using Taylor dispersion analysis and UV area imaging detection

(2014) Alexandra Lavoisier et al.   mAbs

What's fueling the biotech engine—2012 to 2013

(2014) Saurabh (Rob) Aggarwal   NATURE BIOTECHNOLOGY

Optimal charged mutations in the complementarity-determining regions that prevent domain antibody aggregation are dependent on the antibody scaffold

(2014) J. M. Perchiacca et al.   PROTEIN ENGINEERING DESIGN & SELECTION

Identification of aggregation breakers for bevacizumab (Avastin®) self-association through similarity searching and interaction studies

(2013) Y. Westermaier et al.   EUROPEAN JOURNAL OF PHARMACEUTICS AND BIOPHARMACEUTICS

A computational tool to predict the evolutionarily conserved protein-protein interaction hot-spot residues from the structure of the unbound protein

(2013) Neeraj J. Agrawal et al.   FEBS LETTERS

Immunogenicity of therapeutic proteins: Influence of aggregation

(2013) Kirsty D. Ratanji et al.   Journal of Immunotoxicology

Application of a Kosmotrope-Based Solubility Assay to Multiple Protein Therapeutic Classes Indicates Broad Use as a High-Throughput Screen for Protein Therapeutic Aggregation Propensity

(2013) Aaron P. Yamniuk et al.   JOURNAL OF PHARMACEUTICAL SCIENCES

Engineering a therapeutic IgG molecule to address cysteinylation, aggregation and enhance thermal stability and expression

(2013) Andrew Buchanan et al.   mAbs

IgBLAST: an immunoglobulin variable domain sequence analysis tool

(2013) Jian Ye et al.   NUCLEIC ACIDS RESEARCH

Breaking the Aggregation of the Monoclonal Antibody Bevacizumab (Avastin®) by Dexamethasone Phosphate: Insights from Molecular Modelling and Asymmetrical Flow Field-Flow Fractionation

(2013) Marieke Veurink et al.   PHARMACEUTICAL RESEARCH

Impact of deglycosylation and thermal stress on conformational stability of a full length murine igG2a monoclonal antibody: Observations from molecular dynamics simulations

(2013) Xiaoling Wang et al.   PROTEINS-STRUCTURE FUNCTION AND BIOINFORMATICS

Toward aggregation-resistant antibodies by design

(2013) Christine C. Lee et al.   TRENDS IN BIOTECHNOLOGY

Properties of MHC Class I Presented Peptides That Enhance Immunogenicity

(2013) Jorg J. A. Calis et al.   PLoS Computational Biology

Binding and neutralization of vascular endothelial growth factor (VEGF) and related ligands by VEGF Trap, ranibizumab and bevacizumab

(2012) Nicholas Papadopoulos et al.   ANGIOGENESIS

Effect of pH, Temperature, and Salt on the Stability of Escherichia coli- and Chinese Hamster Ovary Cell-Derived IgG1 Fc

(2012) Cynthia H. Li et al.   BIOCHEMISTRY

The impact of glycosylation on monoclonal antibody conformation and stability

(2012) Kai Zheng et al.   mAbs

With or Without Sugar? (A)glycosylation of Therapeutic Antibodies

(2012) Dmitrij Hristodorov et al.   MOLECULAR BIOTECHNOLOGY

Generation and Comparative Characterization of Glycosylated and Aglycosylated Human IgG1 Antibodies

(2012) Dmitrij Hristodorov et al.   MOLECULAR BIOTECHNOLOGY

General strategy for the generation of human antibody variable domains with increased aggregation resistance

(2012) K. Dudgeon et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Engineering Aggregation-Resistant Antibodies

(2012) Joseph M. Perchiacca et al.   Annual Review of Chemical and Biomolecular Engineering

Aggregates in monoclonal antibody manufacturing processes

(2011) María Vázquez-Rey et al.   BIOTECHNOLOGY AND BIOENGINEERING

Prediction of the aggregation propensity of proteins from the primary sequence: Aggregation properties of proteomes

(2011) Virginia Castillo et al.   Biotechnology Journal

Elucidation of Acid-induced Unfolding and Aggregation of Human Immunoglobulin IgG1 and IgG2 Fc

(2011) Ramil F. Latypov et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

PROPKA3: Consistent Treatment of Internal and Surface Residues in Empirical pKaPredictions

(2011) Mats H. M. Olsson et al.   Journal of Chemical Theory and Computation

Developability Index: A Rapid In Silico Tool for the Screening of Antibody Aggregation Propensity

(2011) Timothy M. Lauer et al.   JOURNAL OF PHARMACEUTICAL SCIENCES

Distinct Aggregation Mechanisms of Monoclonal Antibody Under Thermal and Freeze-Thaw Stresses Revealed by Hydrogen Exchange

(2011) Aming Zhang et al.   PHARMACEUTICAL RESEARCH

Acid-Induced Aggregation of Human Monoclonal IgG1 and IgG2: Molecular Mechanism and the Effect of Solution Composition

(2010) Sanjay B. Hari et al.   BIOCHEMISTRY

Design and Application of Antibody Cysteine Variants

(2010) Vladimir Voynov et al.   BIOCONJUGATE CHEMISTRY

Glycosylation influences on the aggregation propensity of therapeutic monoclonal antibodies

(2010) Veysel Kayser et al.   Biotechnology Journal

Association of ranibizumab (Lucentis®) or bevacizumab (Avastin®) with dexamethasone and triamcinolone acetonide: An in vitro stability assessment

(2010) Marieke Veurink et al.   EUROPEAN JOURNAL OF PHARMACEUTICS AND BIOPHARMACEUTICS

Prediction of Aggregation Prone Regions of Therapeutic Proteins

(2010) Naresh Chennamsetty et al.   JOURNAL OF PHYSICAL CHEMISTRY B

Potential aggregation prone regions in biotherapeutics

(2010) Xiaoling Wang et al.   mAbs

Predictive tools for stabilization of therapeutic proteins

(2010) Vladimir Voynov et al.   mAbs

A Humanized Anti-VEGF Rabbit Monoclonal Antibody Inhibits Angiogenesis and Blocks Tumor Growth in Xenograft Models

(2010) Yanlan Yu et al.   PLoS One

Structure-based engineering of a monoclonal antibody for improved solubility

(2010) S.-J. Wu et al.   PROTEIN ENGINEERING DESIGN & SELECTION

Prediction of protein binding regions

(2010) Naresh Chennamsetty et al.   PROTEINS-STRUCTURE FUNCTION AND BIOINFORMATICS

Formulation and manufacturability of biologics

(2009) Steven J Shire   CURRENT OPINION IN BIOTECHNOLOGY

Antivascular endothelial growth factor therapy for neovascular age-related macular degeneration

(2009) Thomas A Ciulla et al.   CURRENT OPINION IN OPHTHALMOLOGY

Aggregation-Prone Motifs in Human Immunoglobulin G

(2009) Naresh Chennamsetty et al.   JOURNAL OF MOLECULAR BIOLOGY

Glycosylation as a strategy to improve antibody-based therapeutics

(2009) Roy Jefferis   NATURE REVIEWS DRUG DISCOVERY

Dynamic Fluctuations of Protein-Carbohydrate Interactions Promote Protein Aggregation

(2009) Vladimir Voynov et al.   PLoS One

Design of therapeutic proteins with enhanced stability

(2009) N. Chennamsetty et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

GROMACS 4:  Algorithms for Highly Efficient, Load-Balanced, and Scalable Molecular Simulation

(2008) Berk Hess et al.   Journal of Chemical Theory and Computation

Contribution of Variable Domains to the Stability of Humanized IgG1 Monoclonal Antibodies

(2007) Roxana M. Ionescu et al.   JOURNAL OF PHARMACEUTICAL SCIENCES